Agios Pharm Net Income From Continuing Ops Over Time
| AGIO Stock | USD 27.96 0.11 0.39% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Agios Pharm Performance and Agios Pharm Correlation. Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Agios Pharm and related stocks such as Denali Therapeutics, Recursion Pharmaceuticals, and Beam Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNLI | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (86.7 M) | (88.2 M) | (36.2 M) | (197.6 M) | 72.8 M | (290.6 M) | (326 M) | (124.4 M) | (422.8 M) | (380.5 M) | (361.5 M) |
| RXRX | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (87 M) | (186.5 M) | (239.5 M) | (292.6 M) | (463.7 M) | (417.3 M) | (396.4 M) |
| BEAM | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (313.7 M) | (376.7 M) | (339.1 M) | (356 M) |
| RCUS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (53.1 M) | (49.6 M) | (84.7 M) | (122.9 M) | 52.8 M | (267 M) | (307 M) | (284 M) | (255.6 M) | (242.8 M) |
| COGT | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (25.5 M) | (34.5 M) | (31.8 M) | (74.8 M) | (72.3 M) | (140.2 M) | (177.7 M) | (255.9 M) | (230.3 M) | (218.8 M) |
| IBRX | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (92.4 M) | (349.8 M) | (417.3 M) | (458.8 M) | (413.6 M) | (372.3 M) | (390.9 M) |
| GLPG | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (37.3 M) | (194.3 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (311 M) | (125.4 M) | (218 M) | (153.1 M) | (1.3 M) | (1.2 M) | (1.2 M) |
| SRPT | (2.3 M) | (2.3 M) | (121.3 M) | (112 M) | (135.8 M) | (220 M) | (267.3 M) | (50.7 M) | (361.9 M) | (715.1 M) | (554.1 M) | (418.8 M) | (703.5 M) | (690.9 M) | 235.2 M | 211.7 M | 222.3 M |
| LQDA | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (29.2 M) | (53.1 M) | (47.6 M) | (59.8 M) | (34.6 M) | (41 M) | (57.6 M) | (130.4 M) | (117.4 M) | (111.5 M) |
Agios Pharm and related stocks such as Denali Therapeutics, Recursion Pharmaceuticals, and Beam Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Agios Pharm | AGIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 88 Sidney Street, |
| Exchange | NASDAQ Exchange |
USD 27.96
Check out Agios Pharm Performance and Agios Pharm Correlation. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Agios Pharm technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.